<DOC>
	<DOCNO>NCT00828854</DOCNO>
	<brief_summary>The addition SNDX-275 AI result maximal abrogation estrogen receptor-α mediated activity inhibit mechanisms resistance aromatase inhibitor . It hypothesize SNDX-275 continue AI increase estimate AI clinical benefit rate ( CBR ) 5 % 25 % acceptable safety profile .</brief_summary>
	<brief_title>A Phase 2 , Multicenter Study Effect Addition SNDX-275 Continued Aromatase Inhibitor ( AI ) Therapy Postmenopausal Women With ER+ Breast Cancer Whose Disease Progressing</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<criteria>1 . Postmenopausal female patient . 2 . Histologically cytologically confirm ER+ breast cancer . 3 . Progressive disease ( PD ) least 3 month treatment 3rd generation AI advance disease set measure RECIST criterion . 4 . At least 1 measurable lesion ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan last imaging perform within 4 week prior study entry . If one measurable lesion locate previously irradiate field , must demonstrate progression accord RECIST criterion . 5 . ECOG 01 . 6 . Laboratory parameter : 1 . Hemoglobin ≥ 9.0 g/dL ; platelet ≥ 100 x109/L ; ANC ≥ 1.5 x 109/L without use hematopoietic growth factor . 2 . Creatinine le 2.5 time upper limit normal institution . 3 . AST ALT less 2.5 time upper limit normal institution . 7 . Able understand give write informed consent comply study procedure . 1 . Discontinuation AI therapy prior study entry . 2 . Less 3 month treatment recent AI . 3 . Rapidly progressive , lifethreatening metastasis , include follow : 1 . Symptomatic lymphangitic metastasis . 2 . Patients know active brain leptomeningeal involvement . 4 . More one prior chemotherapy metastatic disease . 5 . Any chemotherapy within 3 month prior study . 6 . Radiotherapy measurable lesion within 2 month prior study . 7 . Bisphosphonates initiate within 4 week prior study start . 8 . Allergy benzamides inactive component study drug . 9 . Previous treatment entinostat HDAC inhibitor include valproic acid . 10 . Patient currently receive treatment agent list prohibited medication list valproic acid systemic cancer agent 11 . Any concomitant medical condition precludes adequate study treatment compliance assessment , increase patient risk opinion investigator : 1 . Myocardial infarction arterial thromboembolic event within 6 month , experience severe unstable angina , New York Heart Association ( NYHA ) Class III IV disease QTc interval &gt; 0.47 second . 2 . Uncontrolled heart failure hypertension , uncontrolled diabetes mellitus , uncontrolled systemic infection , 3 . Other active malignancy within 5 year exclude basal cell carcinoma cervical intraepithelial neoplasia [ CIN / cervical carcinoma situ ] melanoma situ ) . 12 . Patient currently enrol ( complete within 30 day study drug administration ) another investigational drug study .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>estrogen receptor postive</keyword>
</DOC>